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Aryl hydrocarbon receptor (AHR) is thought to be a crucial factor in the regulation of immune
responses. Many AHR-mediated immunoregulatory mechanisms have been discovered,
and this knowledge may enhance our understanding of the molecular pathogenesis of
autoimmune inflammatory syndromes such as collagen-induced arthritis, experimental
autoimmune encephalomyelitis, and experimental colitis. Recent findings have elucidated
the critical link between AHR and indoleamine 2,3-dioxygenase (IDO) in the development
of regulatory T cells and Th17 cells, which are key factors in a variety of human autoim-
mune diseases. Induction of IDO and IDO-mediated tryptophan catabolism, together with
its downstream products such as kynurenine, is an important immunoregulatory mecha-
nism underlying immunosuppression, tolerance, and immunity. Recent studies revealed
that induction of IDO depends on AHR expression. This review summarizes the most cur-
rent findings regarding the functions of AHR and IDO in immune cells as they relate to
the pathogenesis of autoimmune diseases in response to various stimuli. We also discuss
the potential link between AHR and IDO/tryptophan metabolites, and the involvement of
several novel related factors (such as microRNA) in the development of autoimmune dis-
eases. These novel factors represent potential therapeutic targets for the treatment of
autoimmune disorders.
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ROLES OF AHR IN THE IMMUNE SYSTEM
Aryl hydrocarbon receptor (AHR) is a ligand-activated member of
the Per–Arnt–Sim (PAS) family of basic helix–loop–helix (HLH)
transcription factors. AHR mediates cellular responses to toxins
or its ligands, including TCDD, 6-formylindolo[3,2-b]carbazole
(FICZ), kynurenine, and 2-(1′H-indole-3′-carbonyl)-thiazole-4-
carboxylic acid methyl ester (ITE) (1–4). AHR forms an active
complex in the cytoplasm with chaperone proteins such as heat
shock protein 90 (HSP90), AHR-interacting protein (AIP), and
p23 (5–7). Once bound to its ligands, the AHR complex translo-
cates to the nucleus and binds AHR nuclear translocator (Arnt).
The resultant AHR–Arnt heterodimers bind specific motifs, called
dioxin-responsive elements (DREs), in the promoter region of tar-
get genes. These targets, the so-called AHR battery genes, include
CYP1A1, CYP1A2, CYP1B1, and other members of cytochrome
P450 family (8–11). Several pathways are involved in the regula-
tion of AHR, including proteasomal degradation of AHR, ligand
metabolism by CYP1A1, and formation of the AHR–Arnt complex
(12, 13). One of these pathways involves an inhibitory peptide.
Mimura et al. isolated a cDNA clone that encode a polypeptide
with high similarity to the sequence of the bHLH/PAS of AHR (14).
This polypeptide can repress the transcriptional activity of AHR
by competing with AHR for binding to Arnt and by binding to the
enhancer sequence XRE, upstream of the AHRR gene; therefore,
this peptide is designated AHR repressor or AHRR. Expression of
AHRR is induced by the AHR/Arnt heterodimer through binding
to XRE, resulting in feedback inhibition of AHR. In addition, sev-
eral transcription factors can interact and regulate AHR signaling;
these include STAT-1, STAT3, STAT5, Pai-2, Sp1, c-maf, and Bach2
in certain cell types (15–24). AHR is activated in many immune
cell types, including T cells, B cells, NK cells, macrophages, and
dendritic cells (DCs), as well as in epithelial cells, Langerhans cells,
innate lymphoid cells, intraepithelial lymphocytes, and microglia
(15, 16, 20, 21, 25–40). Depending on the presence of specific lig-
ands, AHR activation may suppress or exacerbate experimental
autoimmune diseases. For examples, TCDD and ITE can suppress
experimental autoimmune encephalomyelitis (EAE), a model of
multiple sclerosis (MS), whereas FICZ exacerbates disease devel-
opment (17, 41–43). Differences in the stability and structure of
these ligands, as well as their affinity for AHR, should be taken
into account when considering their mode of action in the activa-
tion of AHR. In addition, AHR seems to be regulated by unraveled
factors such as transcription factors, tryptophan metabolites, feed-
back regulation of the cytokine network, and microRNA (miR).
Below, we will discuss in detail the factors that may interact with
AHR to modulate immune responses.
IDO AND TRYPTOPHAN METABOLITES
Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme
in extrahepatic catabolism of the essential amino acid tryptophan
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via the kynurenine pathway (44). IDO is constitutively expressed
in placenta, but is also highly expressed in epididymis, gut,
lymph nodes, spleen, thymus, and lung (45). IDO converts
tryptophan into kynurenine and other downstream metabolites,
some with neuroactive properties, such as kynurenic acid, 3-
hydroxykynurenine, quinolinic acid (QUIN), and serotonin. Defi-
ciency or overexpression of IDO can result in changes in the levels
of these neuroactive IDO-mediated metabolites, ultimately lead-
ing to neuronal disorders. For instance, elevated levels of QUIN,
a potently neurotoxic N -methyl-D-aspartate (NMDA) receptor
agonist, can cause not only neurodegenerative conditions such as
Huntington’s disease (46) and Parkinson’s disease (47), but also
infections of the central nervous system and psychiatric diseases
such as depression (48). On the other hand, in pregnant mice,
IDO may play a role in preventing the rejection of allogeneic
fetuses (49). In addition, blocking IDO activity with the compet-
itive inhibitor 1-methyl tryptophan (1-MT) selectively disrupts
the maintenance of pregnancy in mice (49, 50). Consistent with
the observations that IDO induces tolerance in allogeneic fetuses,
IDO expression, especially in DCs, suppresses the T cell response
(49, 51, 52). Various mediators can induce IDO expression and
activity, including IFN-γ, TNF-α, IL-1β, and IL-6 (53–58). Recent
work showed that the induction of IDO depends on AHR (31, 59,
60). Furthermore, kynurenine has been identified as a potent AHR
agonist (2, 61, 62).
Immunoregulatory IDO activity and tryptophan metabolites
participate in the regulation of many cell types, including T
cells, DCs, monocytes, macrophages, and microglia, that play spe-
cific roles in immune responses and regulate the development of
immune-mediated inflammatory diseases (62–66). Alberati-Giani
et al. showed that IFN-γ induced the expression of IDO activity in
immortalized murine macrophages (MT2) and microglial (N11)
cells. IFN-γ-treated MT2 cells, but not N11 cells, were able to pro-
duce detectable amounts of radiolabeled 3-hydroxyanthranilic and
QUIN from L-[5-3H] tryptophan. In addition, Heyes et al. demon-
strated that increased activities of IDO, kynurenine-3-hydroxylase,
and kynureninase in infiltrating primary macrophages may accel-
erate the synthesis of QUIN, L-kynurenine, and kynurenic acid
in conditions of brain inflammation (48). Taken together, these
findings suggested that infiltrating macrophages may contribute
high amount of cerebral QUIN in brain inflammation (48, 67).
Besides, IDO has been demonstrated to be constitutively expressed
in DCs (68). Particularly, CD8α+DC exhibited high functional
activity of IDO while CD8− fraction of DC did not exhibit sig-
nificant enzyme activity (68). Moreover, it has been shown that
the expression of IDO makes CD8+DC treated with IFN-γ capa-
ble of affecting apoptosis of T helper type 1 (Th1) cells (68, 69).
Fallarino et al. also found that tryptophan metabolites such as
3-hydroxyanthranilic and QUIN induce the selective apoptosis
in vitro of murine Th1 cells at relatively low concentrations of
kynurenines (70). Together, IDO and kynurenines metabolites are
able to be induced in various cell types under different stimuli
regulating many immune responses. Modulation of IDO activity
and/or kynurenine pathway may develop therapeutics for inflam-
matory diseases. In addition to IDO, tryptophan 2,3-dioxygenase
(TDO) originated from liver and neuron, is also an important
rate-limiting enzyme in the tryptophan metabolism. TDO plays
a pivotal role in tumor development and various diseases in the
brain (61, 71–73).
The transcriptional regulation of IDO is mediated by two main
pathways, IFN-γ-dependent and -independent, which involve
transcription factors such as NF-κB, STAT-1, and IRF-1 (74). We
will discuss the translational regulation of IDO by AHR in the
following section.
TRANSLATIONAL REGULATION OF IDO
Although the regulatory roles of IDO in tryptophan metabolism in
immune regulation have been extensively studied, the mechanisms
by which IDO is controlled at the pre-, co-, and post-translational
levels are poorly understood. Fujigaki et al. demonstrated that IDO
activity is regulated by post-translational modification: specifi-
cally, IDO activity is inhibited by peroxynitrite due to the nitration
of tyrosine resides (Tyr15, Tyr345, and Tyr353) (75). The same
group also demonstrated that an N-terminal alanine of IDO is
acetylated in IFN-γ-stimulated THP-1 cells, but the biological sig-
nificance of this modification has not been fully investigated (76,
77). In addition, another group found that Tyr115 and Tyr253
in mouse IDO can be phosphorylated, and these phosphory-
lations are required for formation of the IDO/SOCS3 complex
(78). This complex is ubiquitinated and subsequent proteasoma-
lly degraded in DCs. These studies indicate that post-translational
modifications such as nitration and phosphorylation of tyrosine
in IDO may affect IDO/kynurenine-mediated immune regulation.
Recently, we showed that the miR-132/212 cluster participates
in AHR-dependent generation of Th17 cells (79). miRs, 20–22-
nucleotide non-coding RNAs, are a new class of regulators of gene
expression at the posttranscriptional level. miRs binding to the
3′UTR of target mRNAs, leading to translational inhibition and/or
degradation of the targets (80). Although numerous immunoregu-
latory genes are controlled by miRs, to date no miRs targeting IDO
have been identified. According to a widely used computational
miR target prediction tool, microRNA.org, several miRs poten-
tially regulate IDO mRNA (http://www.microrna.org/microrna/
home.do). For example, miR-203 has a putative binding site in
the 3′UTR of IDO in mouse. Interestingly, this miR is induced by
AHR ligands such as TCDD and BaP, and it negatively affects AHR
expression in human cancer cell lines (81). In addition, it has been
reported that miR-203 in macrophage RAW264.7 cells negatively
regulates LPS-induced IL-6 and TNF-α by targeting MyD88 (82).
Considering that AHR inhibits pro-inflammatory cytokines pro-
duction such as IL-6 and TNF-α in LPS-stimulated macrophages
as similarly to miR-203, miR-203 may also be involved in AHR-
mediated regulation of inflammatory responses in macrophages.
Although experimental verification is necessary in order to con-
firm this possible relationship between miR and IDO mRNA,
identification of miR-mediated regulation of the IDO pathway
may shed light on novel mechanisms of immune regulation.
AHR/IDO AXIS IN PATHOGENESIS IN AUTOIMMUNE DISEASE
For several decades, AHR has been studied as an important tran-
scription factor involved in regulation of a large superfamily of
genes encoding cytochrome p450 proteins, which are xenobiotic
metabolizing enzymes. Two independent groups demonstrated
that AHR controls the generation of regulatory T (Treg) cells
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and/or IL-17-producing T helper (Th17) cells in EAE, a mouse
model of MS (17, 41). Because the balance between Treg and Th17
cells is now considered to be more important than the Th1/Th2
balance in regard to the onset of autoimmunity, AHR has attracted
increased attention in the context of immunology. To investigate
the pathophysiological roles of AHR in autoimmunity, several
groups have studied mouse models of autoimmune disease, such as
colitis and rheumatoid arthritis, using AHR-KO mice and/or AHR
ligands (83–85). Meanwhile, the roles of AHR in various immune
cells such as DCs and macrophages have also been investigated
(16, 25, 60). In DCs, AHR positively regulates IDO expression and
subsequent kynurenine production (60). In addition, Kimura et al.
observed reduced phosphorylation of STAT-1 in AHR-deficient
macrophages; by contrast, AHR acts as a negative regulator of
STAT-1 activation in T cells under Th17-polarizing conditions
(15, 16). Thus, the effect of AHR on STAT-1 status is complex, and
may be cell type- or stimulus-dependent. Given that expression of
IDO is predominantly controlled by the IFN-γ/STAT-1 axis, AHR
may positively control STAT-1 activation and subsequent IDO
expression in DCs. More importantly, kynurenine is an agonist
of AHR, and may participate in a positive-feedback loop in AHR
signaling. In both plasma and CSF from MS patients, tryptophan
levels were significantly reduced (86). In addition, IFN-β treat-
ment, a first-line immunomodulatory treatment for MS, causes
elevation of IDO mRNA and plasma or serum kynurenine (87,
88). As well as the observation in MS patients, EAE induction
leads to alteration of the ratio of kynurenine and tryptophan or
IDO expression in brain and spinal cord (89, 90). On the other
hand, in spite of evidence that IDO is induced by IFN-γ, IDO
expression is negatively correlated with IFN-γ mRNA levels in
brain and spinal cord. This observation suggests that IDO activity
inhibits the generation of IFN-γ-producing Th1 cells, a primary
subset of pathogenic T cells (89). Consistent with these findings,
deletion of IDO in mice and treatment with the IDO inhibitor
1-MT result in exacerbated disease symptoms in association with
elevated levels of Th1 cells (89–91). We previously showed that
LPS- or CpG-stimulated AHR-deficient BMDCs co-cultured with
naïve T cells contain a smaller proportion of Treg cells and elevated
levels of Th1 and Th17 (60). Furthermore, the aberrant genera-
tion of each Th-cell subset can be rescued by kynurenine. These
observations indicate that kynurenine generates a tolerogenic con-
dition by controlling not only Th1, but also Th17 and Treg cells.
In addition, it has been reported that AHR participates in type
1 regulatory T (Tr1) cell generation in vitro and in vivo (18, 92,
93). Thus, we cannot exclude the possibility that not only TCDD
and FICZ, but also kynurenine regulates Tr1 cell induction. Taken
together, further investigation of the roles of kynurenine in T cell
differentiation may reveal potential therapeutic strategies for MS.
Thus, further investigation of the roles of kynurenine in T cell
differentiation may reveal potential therapeutic strategies for MS.
Immune regulation through the AHR/IDO axis is summarized in
Figure 1.
FIGURE 1 |TLR ligands trigger transcriptional activation of STAT-1 and
NF-κB, and then induce IDO mRNA. Although AHR forms complex with
STAT-1 and NF-κB in macrophages under pro-inflammatory cytokines
production, whether this complex is appeared in DC or required for IDO
expression is not known. Induced IDO mRNA may be controlled by miR-203
(not investigated), and the activity or amount of IDO protein is regulated at
post-translational modification such as nitration of Tyr and ubiquitin ligation.
Kynurenine catalyzed by IDO induces tolerance via regulating the balance of
TH1, TH17, Tr1, and Treg. Kynurenine may activate the AHR for IDO induction
with autocrine manner, and form AHR/Kynurenine positive-feedback loop.
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PERSPECTIVES OF AHR/IDO AXIS: FROM BENCH TO BEDSIDE
Aryl hydrocarbon receptor and tryptophan metabolites partici-
pate in experimental models of autoimmune diseases (4, 17, 26,
41, 42, 61, 85, 94–96). However, the possible role of AHR in dioxin-
exposed people is still unknown, particularly in autoimmune dis-
orders. Therefore, it will be interesting to examine the expression
of AHR and AHR-related genes in dioxin-affected people with the
aim of identifying the potential link between AHR induction and
dioxin-related autoimmune diseases. Future investigations should
focus on determining whether activation of AHR leads to stimu-
lation of IDO expression, and consequently promotes production
of tryptophan metabolites such as kynurenine, which potentially
mediate the neurological disorders and/or autoimmune diseases
in dioxin-exposed people. Promising therapeutics based on inter-
vention in the AHR/IDO axis may help to improve the health
outcomes of dioxin exposure.
ACKNOWLEDGMENTS
This work was supported by the Kishimoto Foundation and
Project CSK14-02 (for Nam Trung Nguyen) from the Institute
of Biotechnology, Vietnam Academy of Science and Technology.
REFERENCES
1. Nguyen LP, Bradfield CA. The search for endogenous activators of the
aryl hydrocarbon receptor. Chem Res Toxicol (2008) 21:102–16. doi:10.1021/
tx7001965
2. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM,
et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand
that synergistically induces interleukin-6 in the presence of inflammatory sig-
naling. Toxicol Sci (2010) 115:89–97. doi:10.1093/toxsci/kfq024
3. Kerkvliet NI. TCDD: an environmental immunotoxicant reveals a novel path-
way of immunoregulation – a 30-year odyssey. Toxicol Pathol (2012) 40:138–42.
doi:10.1177/0192623311427710
4. Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degradation in autoim-
mune diseases. Cell Mol Life Sci (2007) 64:2542–63. doi:10.1007/s00018-007-
7140-9
5. Perdew GH. Association of the Ah receptor with the 90-kDa heat shock protein.
J Biochem (1988) 263:13802–5.
6. Kazlauskas A, Poellinger L, Pongratz I. Evidence that the co-chaperone p23 regu-
lates ligand responsiveness of the dioxin (aryl hydrocarbon) receptor. J Biochem
(1999) 274:13519–24.
7. Ma Q, Whitlock JP Jr. A novel cytoplasmic protein that interacts with the
Ah receptor, contains tetratricopeptide repeat motifs, and augments the tran-
scriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biochem (1997)
272:8878–84.
8. Sogawa K, Fujii-Kuriyama Y. Ah receptor, a novel ligand-activated transcrip-
tion factor. J Biochem (1997) 122:1075–9. doi:10.1093/oxfordjournals.jbchem.
a021864
9. Burbach KM, Poland A, Bradfield CA. Cloning of the Ah-receptor cDNA reveals
a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA (1992)
89:8185–9. doi:10.1073/pnas.89.17.8185
10. Schrenk D. Impact of dioxin-type induction of drug-metabolizing enzymes
on the metabolism of endo- and xenobiotics. Biochem Pharmacol (1998)
55:1155–62.
11. Tomita S, Jiang HB, Ueno T, Takagi S, Tohi K, Maekawa S, et al. T cell-specific
disruption of arylhydrocarbon receptor nuclear translocator (Arnt) gene causes
resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution.
J Immunol (2003) 171:4113–20. doi:10.4049/jimmunol.171.8.4113
12. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity.
Trends Immunol (2009) 30:447–54. doi:10.1016/j.it.2009.06.005
13. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon recep-
tor: multitasking in the immune system. Annu Rev Immunol (2014) 32:403–32.
doi:10.1146/annurev-immunol-032713-120245
14. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y. Identification of a novel
mechanism of regulation of Ah (dioxin) receptor function. Genes Dev (1998)
13:20–5. doi:10.1101/gad.13.1.20
15. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocar-
bon receptor regulates Stat1 activation and participates in the development
of Th17 cells. Proc Natl Acad Sci USA (2008) 105:9721–6. doi:10.1073/pnas.
0804231105
16. Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl
hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflam-
matory responses. J Exp Med (2009) 206:2027–35. doi:10.1084/jem.20090560
17. Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B. The aryl hydro-
carbon receptor links Th17-cell-mediated autoimmunity to environmental tox-
ins. Nature (2008) 453:106–9. doi:10.1038/nature06881
18. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl
hydrocarbon receptor interacts with c-Maf to promote the differentiation of
type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 11:854–61.
doi:10.1038/ni.1912
19. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, et al. Liver X receptor (LXR)
mediates negative regulation of mouse and human Th17 differentiation. J Clin
Invest (2011) 121:658–70. doi:10.1172/JCI42974
20. Masuda K, Kimura A, Hanieh H, Nguyen NT, Nakahama T, Chinen I, et al.
Aryl hydrocarbon receptor negatively regulates LPS-induced IL-6 production
through suppression of histamine production in macrophages. Int Immunol
(2011) 23:637–45. doi:10.1093/intimm/dxr072
21. Monteiro P, Gilot D, Le Ferrec E, Lecureur V, N’diaye M, Le Vee M, et al.
AhR- and c-maf-dependent induction of beta7-integrin expression in human
macrophages in response to environmental polycyclic aromatic hydrocar-
bons. Biochem Biophys Res Commun (2007) 358:442–8. doi:10.1016/j.bbrc.2007.
04.111
22. De Abrew KN, Phadnis AS, Crawford RB, Kaminski NE, Thomas RS. Regulation
of Bach2 by the aryl hydrocarbon receptor as a mechanism for suppression of
B-cell differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Phar-
macol (2011) 252:150–8. doi:10.1016/j.taap.2011.01.020
23. Nakajima K, Maekawa Y, Kataoka K, Ishifune C, Nishida J, Arimochi H, et al.
The ARNT-STAT3 axis regulates the differentiation of intestinal intraepithelial
TCRαβ?CD8αα? cells. Nat Commun (2013) 4:2112. doi:10.1038/ncomms3112
24. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter
M, et al. Constitutive IDO expression in human cancer is sustained by an
autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014)
5:1038–51.
25. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA.
An interaction between kynurenine and the aryl hydrocarbon receptor can gen-
erate regulatory T cells. J Immunol (2010) 185:3190–8. doi:10.4049/jimmunol.
0903670
26. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, et al. Aryl
hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit
inflammation in the gastrointestinal tract. Gastroenterology (2011) 141:237–48.
doi:10.1053/j.gastro.2011.04.007
27. Sekine H, Mimura J, Oshima M, Okawa H, Kanno J, Igarashi K, et al. Hyper-
sensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-
induced septic shock. Mol Cell Biol (2009) 29:6391–400. doi:10.1128/MCB.
00337-09
28. Matsunawa M, Amano Y, Endo K, Uno S, Sakaki T, Yamada S, et al. The aryl
hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabo-
lism in macrophages. Toxicol Sci (2009) 109:50–8. doi:10.1093/toxsci/kfp044
29. Wu D, Li W, Lok P, Matsumura F,Vogel CF. AhR deficiency impairs expression of
LPS-induced inflammatory genes in mice. Biochem Biophys Res Commun (2011)
410:358–66. doi:10.1016/j.bbrc.2011.06.018
30. Thurmond TS, Staples JE, Silverstone AE, Gasiewicz TA. The aryl hydrocarbon
receptor has a role in the in vivo maturation of murine bone marrow B lympho-
cytes and their response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl
Pharmacol (2000) 165:227–36. doi:10.1006/taap.2000.8942
31. Jux B, Kadow S, Esser C. Langerhans cell maturation and contact hypersensi-
tivity are impaired in aryl hydrocarbon receptor-null mice. J Immunol (2009)
182:6709–17. doi:10.4049/jimmunol.0713344
32. Kadow S, Jux B, Zahner SP, Wingerath B, Chmill S, Clausen BE, et al. Aryl hydro-
carbon receptor is critical for homeostasis of invariant gammadelta T cells in
the murine epidermis. J Immunol (2011) 187:3104–10. doi:10.4049/jimmunol.
1100912
33. Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, et al.
AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues
via pathways dependent on and independent of Notch. Nat Immunol (2011)
13:144–51. doi:10.1038/ni.2187
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 551 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nguyen et al. Dioxin receptor and IDO
34. Lee JS, Cella M, Colonna M. AHR and the transcriptional regulation of type-
17/22 ILC. Front Immunol (2012) 3:1. doi:10.3389/fimmu.2012.00010
35. Kiss EA, Diefenbach A. Role of the aryl hydrocarbon receptor in controlling
maintenance and functional programs of RORγt(+) innate lymphoid cells and
intraepithelial lymphocytes. Front Immunol (2012) 3:124. doi:10.3389/fimmu.
2012.00124
36. Qiu J, Heller JJ, Guo X. The aryl hydrocarbon receptor regulates gut immu-
nity through modulation of innate lymphoid cells. Immunity (2012) 36:92–104.
doi:10.1016/j.immuni.2011.11.011
37. Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, et al.
Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon
receptor activation. Cell (2011) 147:629–40. doi:10.1016/j.cell.2011.09.025
38. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspec-
tive on potential roles in the immune system. Immunology (2009) 127:299–311.
doi:10.1111/j.1365-2567.2009.03054.x
39. Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function.
Swiss Med Wkly (2012) 142:w13592. doi:10.4414/smw.2012.13592
40. Wagage S, John B, Krock BL, Hall AO, Randall LM, Karp CL, et al. The aryl
hydrocarbon receptor promotes IL-10 production by NK cells. J Immunol (2014)
192:1661–70. doi:10.4049/jimmunol.1300497
41. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control
of Treg and Th17 cell differentiation by the aryl hydrocarbon receptor. Nature
(2008) 453:65–71. doi:10.1038/nature06880
42. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ,
et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells
and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl
Acad Sci USA (2010) 107:20768–73. doi:10.1073/pnas.1009201107
43. Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B. Differential influ-
ences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and
in vivo. PLoS One (2013) 8:e79819. doi:10.1371/journal.pone.0079819
44. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immuno-
suppression by starvation? Immunol Today (1999) 20:469–73. doi:10.1016/
S0167-5699(99)01520-0
45. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice
initiated by indoleamine 2,3-dioxygenase. J Biol Chem (1986) 261:3648–53.
46. Reynolds GP, Pearson SJ. Increased brain 3-hydroxykynurenine in Huntington’s
disease. Lancet (1989) 2:979–80. doi:10.1016/S0140-6736(89)90987-2
47. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, et al. Kynure-
nine pathway abnormalities in Parkinson’s disease. Neurology (1992) 42:1702–6.
doi:10.1212/WNL.42.9.1702
48. Heyes MP, Saito K, Major EO, Milstien S, Markey SP,Vickers JH. A mechanism of
quinolinic acid formation by brain in inflammatory neurological disease. Atten-
uation of synthesis from L-tryptophan by 6- chlorotryptophan and 4-chloro-3-
hydroxyanthranilate. Brain (1993) 116:1425–50. doi:10.1093/brain/116.6.1425
49. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Pre-
vention of allogeneic fetal rejection by tryptophan catabolism. Science (1998)
281:1191–3. doi:10.1126/science.281.5380.1191
50. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, et al. Preven-
tion of T cell-driven complement activation and inflammation by tryptophan
catabolism during pregnancy. Nat Immunol (2001) 2:64–8. doi:10.1038/83183
51. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells express-
ing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002)
168:3771–6. doi:10.4049/jimmunol.168.8.3771
52. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of
allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing den-
dritic cells: mediation of suppression by tryptophan metabolites. J Exp Med
(2002) 196:447–57. doi:10.1084/jem.20020052
53. Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits
indoleamine 2,3-dioxygenase expression in human monocytes. Blood (1994)
83:1408–11.
54. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase
by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial
cells. Cytokine (2000) 12:588–94. doi:10.1006/cyto.1999.0661
55. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation
of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha.
J Interferon Cytokine Res (2003) 23:413–21. doi:10.1089/107999003322277829
56. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, Dantzer R, et al.
Bacille Calmette-Guérin inoculation induces chronic activation of peripheral
and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis (2005) 192:537–44.
doi:10.1086/431603
57. Connor TJ, Starr N, O’Sullivan JB, Harkin A. Induction of indolamine 2,3-
dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic
inflammatory challenge: a role for IFN-gamma? Neurosci Lett (2008) 441:29–34.
doi:10.1016/j.neulet.2008.06.007
58. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, et al. The sig-
nal transducer and activator of transcription 1alpha and interferon regulatory
factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by
lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and
nuclear factor-kappaB pathways, and synergistic effect of several proinflamma-
tory cytokines. J Biochem (2006) 139:655–62. doi:10.1093/jb/mvj072
59. Vogel CFA, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon recep-
tor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Bio-
phys Res Commun (2008) 375:331–5. doi:10.1016/j.bbrc.2008.07.156
60. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al.
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenic-
ity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA (2010)
107:19961–6. doi:10.1073/pnas.1014465107
61. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An
endogenous tumour-promoting ligand of the human aryl hydrocarbon recep-
tor. Nature (2011) 478:197–203. doi:10.1038/nature10491
62. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl
hydrocarbon receptor control of a disease tolerance defence pathway. Nature
(2014) 511:184–90. doi:10.1038/nature13323
63. Guillemin GJ, Kerr SJ, Pemberton LA, Smith DG, Smythe GA, Armati PJ, et al.
IFN-beta1b induces kynurenine pathway metabolism in human macrophages:
potential implications for multiple sclerosis treatment. J Interferon Cytokine Res
(2001) 21(12):1097–101. doi:10.1089/107999001317205231
64. Jung ID, Lee CM, Jeong YI, Lee JS, Park WS, Han J, et al. Differential regulation
of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma
in murine bone marrow derived dendritic cells. FEBS Lett (2007) 581:1449–56.
doi:10.1016/j.febslet.2007.02.073
65. O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon
N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated
by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2009)
14:511–22. doi:10.1038/sj.mp.4002148
66. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al.
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by
dendritic cells. Nat Immunol (2011) 12:870–8. doi:10.1038/ni.2077
67. Alberati-Giani D, Ricciardi-Castagnoli P, Köhler C, Cesura AM. Regulation
of the kynurenine metabolic pathway by interferon-gamma in murine cloned
macrophages and microglial cells. J Neurochem (1996) 66:996–1004. doi:10.
1046/j.1471-4159.1996.66030996.x
68. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, et al.
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+)
dendritic cells. Int Immunol (2002) 14:65–8. doi:10.1093/intimm/14.1.65
69. Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona
C, et al. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic
cells expressing indoleamine 2,3-dioxygenase. J Immunol (2001) 167:708–14.
doi:10.4049/jimmunol.167.2.708
70. Fallarino F, Grohmann U, Vacca C, Orabona C, Spreca A, Fioretti MC,
et al. T cell apoptosis by kynurenines. Adv Exp Med Biol (2003) 527:183–90.
doi:10.1007/978-1-4615-0135-0_21
71. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto
K, et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological
neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 2:8.
doi:10.1186/1756-6606-2-8
72. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, et al.
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-
dioxygenase. Proc Natl Acad Sci USA (2012) 109:2497–502. doi:10.1073/pnas.
1113873109
73. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, Teo C, et al. The kynure-
nine pathway in brain tumor pathogenesis. Cancer Res (2012) 72:5649–57.
doi:10.1158/0008-5472.CAN-12-0549
74. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: reg-
ulation by inflammatory cytokines. Front Neurosci (2014) 8:12. doi:10.3389/
fnins.2014.00012
www.frontiersin.org October 2014 | Volume 5 | Article 551 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nguyen et al. Dioxin receptor and IDO
75. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, et al. Nitra-
tion and inactivation of IDO by peroxynitrite. J Immunol (2006) 176:372–9.
doi:10.4049/jimmunol.176.1.372
76. Fujigaki H, Takahashi K, Fujigaki S, Masuda J, Takikawa O, Markey SP, et al. Post-
translational modification of indoleamine 2,3-dioxygenase: N-terminal modifi-
cation and nitration. Int Congr Ser (2007) 1304:41–5. doi:10.1007/s00216-012-
5946-2
77. Fujigaki H, Seishima M, Saito K. Posttranslational modification of indoleamine
2,3-dioxygenase. Anal Bioanal Chem (2012) 403:1777–82. doi:10.1007/s00216-
012-5946-2
78. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3
drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and
antagonizes IDO-dependent tolerogenesis. Proc. Natl Acad Sci USA (2008)
105:20828–33. doi:10.1073/pnas.0810278105
79. Nakahama T, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, et al. Aryl
hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster
promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad
Sci U S A (2013) 110:11964–9. doi:10.1073/pnas.1311087110
80. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell (2009)
136:215–33. doi:10.1016/j.cell.2009.01.002
81. Li D, Liu C, Yu H, Zeng X, Xing X, Chen L, et al. AhR is negatively regulated by
miR-203 in response to TCDD or BaP treatment. Toxicol Res (2014) 3:142–51.
doi:10.1039/c3tx50083g
82. Wei J, Huang X, Zhang Z, Jia W, Zhao Z, Zhang Y, et al. MyD88 as a target of
microRNA-203 in regulation of lipopolysaccharide or Bacille Calmette-Guerin
induced inflammatory response of macrophage RAW264.7 cells. Mol Immunol
(2013) 55:303–9. doi:10.1016/j.molimm.2013.03.004
83. Takamura T, Harama D, Matsuoka S, Shimokawa N, Nakamura Y, Okumura K,
et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dex-
tran sodium sulfate-induced colitis in mice. Immunol Cell Biol (2010) 88:685–9.
doi:10.1038/icb.2010.35
84. Furumatsu K, Nishiumi S, Kawano Y, Ooi M, Yoshie T, Shiomi Y, et al. A role
of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci (2011)
56:2532–44. doi:10.1007/s10620-011-1643-9
85. Nakahama T, Kimura A, Nguyen NT, Chinen I, Hanieh H, Nohara K, et al.
Aryl hydrocarbon receptor deficiency in T cells suppresses the development
of collagen-induced arthritis. Proc Natl Acad Sci USA (2011) 108:14222–7.
doi:10.1073/pnas.1111786108
86. Monaco F, Fumero S, Mondino A, Mutani R. Plasma and cerebrospinal fluid
tryptophan in multiple sclerosis and degenerative diseases. J Neurol Neurosurg
Psychiatry (1979) 42:640–1. doi:10.1136/jnnp.42.7.640
87. Amirkhani A, Rajda C, Arvidsson B, Bencsik K, Boda K, Seres E, et al. Interferon-
beta affects the tryptophan metabolism in multiple sclerosis patients. Eur J Neu-
rol (2005) 12:625–31. doi:10.1111/j.1468-1331.2005.01041.x
88. Durastanti V, Lugaresi A, Bramanti P, Amato M, Bellantonio P, De Luca G, et al.
Neopterin production and tryptophan degradation during 24-months therapy
with interferon beta-1a in multiple sclerosis patients. J Transl Med (2011) 9:42.
doi:10.1186/1479-5876-9-42
89. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine
2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.
J Neuroimmunol (2002) 129:186–96. doi:10.1016/S0165-5728(02)00176-5
90. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, et al. Indolamine 2,3-
dioxygenase is expressed in the CNS and down-regulates autoimmune inflam-
mation. FASEB J (2005) 19:1347–9. doi:10.1096/fj.04-3228fje
91. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, Li H, et al. IDO upregulates regu-
latory T cells via tryptophan catabolite and suppresses encephalitogenic T cell
responses in experimental autoimmune encephalomyelitis. J Immunol (2010)
185:5953–61. doi:10.4049/jimmunol.1001628
92. Wu HY, Quintana FJ, da Cunha AP, Dake BT, Koeglsperger T, Starossom SC, et al.
In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling.
PLoS One (2011) 6:e23618. doi:10.1371/journal.pone.0023618
93. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. Activa-
tion of the aryl hydrocarbon receptor induces human type 1 regulatory T
cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 11:846–53.
doi:10.1038/ni.1915
94. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment
of autoimmune neuroinflammation with a synthetic tryptophan metabolite.
Science (2005) 310:850–5. doi:10.1126/science.1117634
95. Nguyen NT, Hanieh H, Nakahama T, Kishimoto T. The roles of aryl hydro-
carbon receptor in immune responses. Int Immunol (2013) 25:335–43. doi:10.
1093/intimm/dxt011
96. Nguyen NT, Nakahama T, Kishimoto T. Aryl hydrocarbon receptor and experi-
mental autoimmune arthritis. Semin Immunopathol (2013) 35:637–44. doi:10.
1007/s00281-013-0392-6
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 30 July 2014; paper pending published: 05 September 2014; accepted: 16
October 2014; published online: 29 October 2014.
Citation: Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH and Kishimoto T
(2014) Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune
disease research. Front. Immunol. 5:551. doi: 10.3389/fimmu.2014.00551
This article was submitted to Immunological Tolerance, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Nguyen, Nakahama, Le, Van Son, Chu and Kishimoto. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Immunological Tolerance October 2014 | Volume 5 | Article 551 | 6
